Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial-Reference-Cited by-同舟云学术

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Published:2015-11 Issue:6 Volume:9 Page:758-769
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Moriarty Patrick M.,Thompson Paul D.,Cannon Christopher P.,Guyton John R.,Bergeron Jean,Zieve Franklin J.,Bruckert Eric,Jacobson Terry A.,Kopecky Stephen L.,Baccara-Dinet Marie T.,Du Yunling,Pordy Robert,Gipe Daniel A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;Circulation,2013

2. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary;Jacobson;J Clin Lipidol,2014

3. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

4. Diagnosis, prevention, and management of statin adverse effects and intolerance: Proceedings of a Canadian Working Group Consensus Conference;Mancini;Can J Cardiol,2011

5. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study;Bruckert;Cardiovasc Drugs Ther,2005

Cited by 388 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy;International Journal of Molecular Sciences;2024-01-29

2. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

3. Special Patient Populations;Clinical Lipidology;2024

4. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024;Diabetes Care;2023-12-11

5. PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives;Current Molecular Pharmacology;2023-12